



NDA 21-014/S-013
NDA 21-285/S-008

Novartis Pharmaceuticals Corporation
Attention: Peter D. McArdle, D.V.M.
Director, Drug Regulatory Affairs
One Health Plaza
East Hanover, New Jersey 07936-1080

Dear Dr. McArdle:

Please refer to your supplemental new drug applications dated December 13, 2004, received December 14, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Trileptal (oxcarbazepine) tablets and oral suspension.

Your submission of August 31, 2005 constituted a complete response to our June 14, 2005 action letter.

These amended supplemental new drug applications propose the use of Trileptal (oxcarbazepine) tablets and oral solution for use as adjunctive therapy in the treatment of partial seizures in children with epilepsy aged two to four years.

We have completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions "**FPL for approved supplement NDA 21-014/S-013 and NDA 21-285/S-008.**" Approval of these submissions by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

We remind you of your commitment to submit updated specifications and calibration information prior to commercial use of the 5ml syringe.

NDA 21-014/S-013

NDA 21-285/S-008

Page 2

Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package inserts directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Courtney Calder, Pharm.D., Regulatory Project Manager, at (301) 796-1050.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Russell Katz
10/28/2005 11:15:07 AM